4.6 Article

COL1A1 as a Potential Prognostic Marker and Therapeutic Target in Non-small Cell Lung Cancer

Journal

CURRENT BIOINFORMATICS
Volume 17, Issue 10, Pages 909-923

Publisher

BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1574893617666220114141705

Keywords

non-small cell lung cancer (NSCLC); chemosensitivity; bioinformatics analysis; differentially expressed genes (DEGs); prognosis

Ask authors/readers for more resources

In this study, hub targets associated with non-small cell lung cancer (NSCLC) were identified using multiple databases. The gene COL1A1 was found to be a potential prognostic marker and therapeutic target for NSCLC.
Background Nowadays, non-small cell lung cancer (NSCLC) is a common and highly fatal malignancy worldwide. Therefore, identifying the potential prognostic markers and therapeutic targets is urgent for patients. Objective This study aimed at finding hub targets associated with NSCLC using multiple databases. Methods Differentially expressed genes (DEGs) from Genome Expression Omnibus (GEO) cohorts were employed for the enrichment analyses of Gene Ontology (GO) terms and the Kyoto Encyclopedia of Genes and Genome (KEGG) pathways. Candidate key genes, filtered from the topological parameter 'Degree' and validated using the Cancer Genome Atlas (TCGA) cohort, were analyzed for their association with clinicopathological features and prognosis of NSCLC. Meanwhile, immunohistochemical cohort analyses and biological verification were further evaluated. Results A total of 146 DEGs were identified following data preprocessing, and a protein-protein interaction (PPI) systematic network was constructed based on them. The top ten candidate core genes were further extracted from the above PPI network by using 'Degree' value, among which COL1A1 was shown to associate with overall survival (OS) of NSCLC as determined by using the Kaplan-Meier analysis (p=0.028), and could serve as an independent prognostic factor for OS in NSCLC patients (HR, 0.814; 95% CI, 0.665-0.996; p=0.046). We then analyzed the clinical stages, PPI, mutations, potential biological functions, and immune regulations of COL1A1 in NSCLC patients using multiple bioinformatics tools, including GEPIA, GeneMANIA, cBioPortal, GESA, and TISIDB. Finally, we further experimentally validated the overexpression of COL1A1 in NSCLC samples and found that inhibition of COL1A1 expression moderately sensitized NSCLC cells to cisplatin. Conclusion Thus, our results showed that COL1A1 may serve as a potential prognostic marker and therapeutic target in NSCLC.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available